A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

Trial Identifier: D967MC00001
Sponsor: AstraZeneca
Collaborator:
Daiichi Sankyo Co., Ltd.
Start Date: December 2020
Primary Completion Date: January 2023
Study Completion Date: July 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Danish Translation
Spanish Translation
Spanish Translation
French Translation
French Translation
Italian Translation
Japanese Translation
Korean Translation
Dutch Translation

Trial Locations

Country Location
BE Anderlecht, BE, 1070
CA, CA Toronto, CA, CA, M5G 2M9
DK Copenhagen, DK, 2100
ES Barcelona, ES, 08035
ES Madrid, ES, 28041
ES Madrid, ES, 28050
ES Pamplona, ES, 31008
ES Sevilla, ES, 41013
FR Bordeaux, FR, 33076
FR Lyon Cedex 08, FR, 69008
FR Villejuif Cedex, FR, 94805
IT Milan, IT, 20141
IT MILANO, IT, 20162
IT Napoli, IT, 80131
JP Chuo-ku, JP, 104-0045
JP Kashiwa, JP, 277-8577
JP Suita-shi, JP, 565-0871
KR Seoul, KR, 03080
KR Seoul, KR, 03722
KR Seoul, KR, 06351
US, CA Santa Rosa, CA, US, 95403
US, IN Muncie, IN, US, 47303
US, MA Boston, MA, US, 02215
US, MA Boston, MA, US, 02115
US, NJ Middletown, NJ, US, 07748
US, NY Commack, NY, US, 11725
US, NY New York, NY, US, 10021
US, NY West Harrison, NY, US, 10604
US, TX Houston, TX, US, 77030
US, VA Fairfax, VA, US, 22031